Following Bristol-Myers Squibb’s acquisition of Amylin, AstraZeneca will make a payment to Amylin, as a wholly owned subsidiary of Bristol-Myers Squibb, in the amount of approximately $3.4 billion in cash. Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion. Wikipedia, Official currency of the United States and its territories per the Coinage Act of 1792. San Diego-based Amylin Pharmaceuticals Inc. has lured suitors such as Pfizer Inc., AstraZeneca Plc. Laura Hortas +1 609-252-4587 laura.hortas@bms.com. Wikipedia, This will create an email alert. This transaction will be dilutive to AstraZeneca’s Core and Reported EPS in 2012 and 2013, with both measures becoming accretive from 2014. In addition, I would like to acknowledge and thank the dedicated employees of Amylin whose tireless efforts are responsible for creating the tremendous value that is being recognized today by two of the most respected companies in the pharmaceutical industry.”. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. ONGLYZA has been submitted for regulatory approval in 93 countries and is approved in 77 countries including the US, Canada, Mexico, EU, India, Brazil and China. Jennifer Fron Mauer +1 609-252-6579 jennifer.mauer@bms.com; Metreleptin, a leptin analog currently under review at the US Food and Drug Administration (FDA) for the treatment of diabetes and/or hypertriglyceridema (high levels of triglycerides in the bloodstream) in patients with rare forms of inherited or acquired lipodystrophy; A state-of-the-art sterile production facility in Ohio. The agreement also provides for the parties to effect, subject to customary conditions, a merger to be completed following the completion of the tender offer which would result in all shares not tendered in the tender offer being converted into the right to receive $31.00 per share in cash. Drugs.com Mobile Apps. We encourage you to read the privacy policy of every website you visit. Other allergic adverse reactions have occurred in patients with unknown antibody status. Amylin Pharmaceuticals, Inc. Amylin Pharmaceuticals, Inc. is now part of AstraZeneca. AstraZeneca (LSE: AZN.L - news) and Bristol-Myers Squibb today announced that following the successful completion of the acquisition of Amylin Pharmaceuticals (NasdaqGS: AMLN - news) by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. The total value of the transaction, including Amylin’s net debt and a contractual payment obligation to Eli Lilly and Company, together totalling about $1.7 billion, is approximately $7 billion. The acquisition has been unanimously approved by the boards of directors of Bristol-Myers Squibb and Amylin. It is made by Amylin Pharmaceuticals and commercialized by AstraZeneca. The board of directors of Amylin has unanimously recommended that Amylin’s stockholders tender their shares to the tender offer. Wikipedia, American pharmaceutical company, headquartered in New York City. Citi and Evercore are serving as financial advisers to Bristol-Myers Squibb in connection with the acquisition and Kirkland & Ellis LLP is its legal adviser. Bristol-Myers Squibb, AstraZeneca/Amylin. Vediamo di seguito la cronologia delle acquisizioni operate da AstraZeneca. Although Amylin Pharmaceuticals and AstraZeneca Pharmaceuticals LP have a … Bank of America Merrill Lynch is serving as financial adviser to AstraZeneca in connection with the transactions and Davis Polk & Wardwell LLP and Covington & Burling LLP are its legal advisers. AstraZeneca and Bristol-Myers Squibb further expand their ongoing diabetes alliance, following the completion of Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals. Veeva ID: Z4-25396Date of next review: August 2022. Amylin is a pancreatic β -cell hormone that produces effects in several different organ systems. Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialise select investigational drugs for type 2 diabetes.